The improvement of Alzheimer's clinical trial patient access through diagnostic criteria
This article will review the importance of early detection in emerging markets characterised by a predominance of undiagnosed cases, and the impact of new criteria on drug development in terms of trial design, conduct, and subject selection in Alzheimer’s Disease (AD) trials.
